U.S. Serial No.: 10/785,668 -2-

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please amend pending claims 1-5, and 8 as noted below.

- 1. (Currently Amended) A method for treating constipation in a patient receiving opioids chronically, comprising administering orally to the patient receiving opioids chronically a quaternary derivative of noroxymorphone in an amount to achieve laxation within 24 hours, wherein said amount is such that peak plasma concentrations of the quaternary derivative of noroxymorphone do not exceed 100 ng/ml.
- 2. (Currently Amended) The method of claim 1, wherein the patient is receiving an oral dose of between 30 and 100 mg/day of methodone (or a dose of another opioid which is a morphine equivalent dose of between 30 and 100 mg/day of methodone).
- 3. (Currently Amended) The method of claim 1, wherein the patient is receiving an oral dose of between 41 and 100 mg/day of methadone (or a dose of another opioid which is a morphine equivalent dose of between 41 and 100 mg/day of methadone).
- 4. (Currently Amended) The method of claim 1, wherein the <u>quaternary derivative of</u> noroxymorphone is administered in an amount to achieve laxation is within 10 hours.
- 5. (Currently Amended) The method of claim 1, wherein the amount dose of the quaternary derivative of noroxymorphone is between 0.3 and 3.0 mg/kg per day.
- 6. (Original) The method of claim 1, wherein the quaternary derivative of noroxymorphone is not enteric coated.
- 7. (Original) The method of claim 1, wherein the quaternary derivative of noroxymorphone is enteric coated.

8. (Currently Amended) The method of any of claims 1-[[5]]7, wherein the quaternary derivative or noroxymorphone is methylnaltrexone.